In early 2011 Prozomix began the development of proprietary high-throughput cloning technology in response to the ever increasing requirement for larger numbers of non-engineered natural (native) biocatalysis enzymes (KREDs / ADHs / EREDs / nitrilases / NHases /… View full article »
We are delighted to announce a collaboration with CLEA Technologies B.V., an internationally recognised innovative leader in enzyme immobilisation and biocatalytic process development, that will combine the proven and powerful GRASP™ high-throughput novel biocata… View full article »
April 2nd, 2012 - Prozomix is delighted to announce the appointment of Meiji Seika Pharma Co., LTD., a Japanese public company, as our Exclusive Distributor in Japan. Meiji now hosts a Japanese version of the Prozomix enzyme catalogue and other content on their w… View full article »
Prozomix is pleased to announce that as part of a 17 strong academic / commercial EU consortium, it has been awarded a highly competitive research grant under the FP7-KBBE Programme. The €7.8 M "KYROBIO" Project (Grant No. 289646) aims to "discover, develop and d… View full article »
